TYHT Stock: From $11.94 To $16.23 (35.93% Increase) Explanation

By Amit Chowdhry ● May 4, 2021
  • The stock price of Shineco Inc (NASDAQ: TYHT) increased from $11.94 to $16.23 (up 35.93%) today. This is why it happened.

The stock price of Shineco Inc (NASDAQ: TYHT) – a producer and distributor of Chinese herbal medicines, organic agricultural, and hemp products – increased from $11.94 to $16.23 (35.93%) increase today. Investors appear to be responding positively to the company announcing that it and Mayah Biological Holdings Limited, a British Virgin Islands Company headquartered in Taiwan Biomedical Park, had signed a Proposal for Purchase of Equity Interest of Mayah Biological Holding Limited (the Proposal) with respect to the potential purchase of at least 51% equity interests in Mayah Biological by Shineco.

The parties to the Proposal had agreed to sign a definitive agreement after going through the due diligence progress by both parties. But there is no guarantee that the parties to the Proposal will enter into a definitive agreement. If a definitive agreement is not entered into for any reason, then none of the parties to the Proposal will have any liability to any other party based on anything related to the non-binding terms of the Proposal.

Mayah Biological is a biotechnology company that focuses on the development of chemical and biomedicine in the pre-clinical and clinical stages. And Mayah Biological is committed to developing new biological targets of small molecule and protein medicines for the treatment of tumors, diabetes, and drug abuse.

Mayah Biological has a strong scientific research team consisting of professors in the field of medicine research and development from prestigious universities in the United States like professors of the Department of Molecular and Medical Pharmacology at the University of California, Los Angeles School of Medicine, professors of the Department of Molecular and Cellular Biochemistry at the University of Kentucky Cancer Center, and professors of the Department of Pharmaceutical Sciences at University of Kentucky School of Pharmacy. And each member of the scientific research team has over 30 years of working experience in biotechnology and pharmacy with many scientific research accomplishments.

Mayah Biological is currently planning to build over 10 medicine pipelines, covering medicine R&D in the fields of tumors, diabetes, and antidotes. One drug completed clinical trial phase 2, one cancer drug is ready for clinical trial phase 2, and 3 other cancer drugs have completed preclinical preparations to enter clinical trial phase 1. Many drugs in the pipeline are first-in-class drugs with no similar products in the market. And Mayah Biological takes advantage of the combination of years of medicine R&D experience of the scientific research team and AI medicine R&D technology and is also engaged in the R&D of new me-better medicine with known targets.

By using AI medicine R&D technology and utilizing its scientific research team’s strengths in basic research, medicine design, chemical synthesis, activity testing, animal models, and pathology, Mayah Biological believes it will be able to save about 3-5 years in drug development as compared with traditional medicine R&D companies, decrease the uncertainty of medicine R&D, improve the success rate of medicine R&D, greatly reduce the costs and risks of R&D research, and realize its interest to the most extent.

Mayah Biological is currently introducing medicine pipelines and carrying out follow-up R&D of some pipelines under clinical trials. And Mayah Biological believes that its medicines will have broad market prospects and sustainable profitability. For example, Mayah Biological is currently developing proteasome inhibitors and new tumor inhibitors and analgesics.

It is estimated that from 2024 to 2031, the total annual sales revenue of proteasome inhibitors for the treatment of prostate cancer will be $14.611 billion per year, the total sales revenue for the treatment of multiple myeloma will be $2.081 billion per year, and the total annual sales revenue of new tumor inhibitors and analgesics will be $3.247 billion per year.

Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.